Astrana Health (NASDAQ:ASTH) Given New $50.00 Price Target at Truist Financial

Astrana Health (NASDAQ:ASTH) had its price objective cut by equities researchers at Truist Financial from $59.00 to $50.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s target price indicates a potential upside of 69.61% from the stock’s previous close.

Several other equities research analysts also recently issued reports on the company. Macquarie raised Astrana Health to a “hold” rating in a report on Monday, December 16th. BTIG Research boosted their price target on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. TD Cowen started coverage on Astrana Health in a report on Monday, October 14th. They set a “buy” rating and a $66.00 price target on the stock. Robert W. Baird upped their target price on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, KeyCorp started coverage on Astrana Health in a report on Friday, October 11th. They issued a “sector weight” rating on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Astrana Health has an average rating of “Moderate Buy” and a consensus price target of $63.67.

Astrana Health Price Performance

NASDAQ:ASTH opened at $29.48 on Monday. Astrana Health has a 1-year low of $29.35 and a 1-year high of $63.20. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The firm has a fifty day simple moving average of $39.55 and a 200 day simple moving average of $47.00. The stock has a market capitalization of $1.66 billion, a PE ratio of 22.68, a P/E/G ratio of 1.80 and a beta of 1.20.

Astrana Health (NASDAQ:ASTH) last released its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $478.71 million during the quarter, compared to analysts’ expectations of $462.01 million. During the same period last year, the business earned $0.47 earnings per share. On average, research analysts expect that Astrana Health will post 1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Astrana Health

Large investors have recently made changes to their positions in the business. GAMMA Investing LLC purchased a new stake in Astrana Health during the 3rd quarter valued at about $34,000. Nisa Investment Advisors LLC bought a new position in shares of Astrana Health in the 3rd quarter worth approximately $35,000. KBC Group NV bought a new position in shares of Astrana Health in the 3rd quarter worth approximately $70,000. Quarry LP bought a new position in shares of Astrana Health in the 3rd quarter worth approximately $77,000. Finally, Quest Partners LLC bought a new position in shares of Astrana Health in the 3rd quarter worth approximately $133,000. 52.77% of the stock is currently owned by institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.